New hope for Tough-to-Treat amyloidosis patients
NCT ID NCT06569147
Summary
This study is testing a drug called elranatamab in people with AL amyloidosis that has returned or hasn't responded to previous treatments. The first part finds the safest dose, and the second part checks how well it works at that dose. About 49 participants will receive the drug to see if it can reduce the harmful proteins causing their disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.